TriSalus Life Sciences (TLSIW) Enterprise Value (2021 - 2026)

TriSalus Life Sciences has reported Enterprise Value for 6 years, with the latest figure at -$56.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 335.02% year-over-year to -$56.6 million; the trailing twelve-month figure through Mar 2026 stood at -$56.6 million (down 335.02% YoY), and the FY2025 full-year result was -$20.4 million, down 139.75% from the prior year.
• Enterprise Value for Q1 2026 stood at -$56.6 million, down from -$20.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$69182.0 in Q2 2022, with the low at -$56.6 million in Q1 2026.
• Historically, Enterprise Value has averaged -$13.9 million across 5 years, with a median of -$11.5 million in 2023.
• The largest YoY upside for Enterprise Value was 47.21% in 2024 against a maximum downside of 15750.93% in 2024.
• TriSalus Life Sciences' Enterprise Value stood at -$9.4 million in 2022, then declined by 25.1% to -$11.8 million in 2023, then gained by 27.61% to -$8.5 million in 2024, then tumbled by 139.75% to -$20.4 million in 2025, then sank by 176.69% to -$56.6 million in 2026.
• The last three Enterprise Value figures came in at -$56.6 million (Q1 2026), -$20.4 million (Q4 2025), and -$22.7 million (Q3 2025), per Business Quant data.